Bisphosphonates induce apoptosis in human breast cancer cell lines - Wikidata - awgldk - TriplyDB

Bisphosphonates induce apoptosis in human breast cancer cell lines

Bisphosphonates induce apoptosis in human breast cancer cell lines

http://www.wikidata.org/entity/Q28344185

about

Addition of pamidronate to chemotherapy for the treatment of osteosarcoma Direct effects of bisphosphonates on breast cancer cells.Actions of bisphosphonates in animal models of breast cancer Should all adjuvant breast cancer patients receive a bisphosphonate?Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.Bisphosphonates regulate cell growth and gene expression in the UMR 106-01 clonal rat osteosarcoma cell line Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines.Enhancement of hybridoma formation, clonability and cell proliferation in a nanoparticle-doped aqueous environment.New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases.Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis.Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy.Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial.Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk.Direct antitumour activity of zoledronic acid: preclinical and clinical data.Synthesis, biological evaluation and molecular docking studies of trans-indole-3-acrylamide derivatives, a new class of tubulin polymerization inhibitors Reversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitors A promising approach for treatment of tumor-induced bone diseases: utilizing bisphosphonate derivatives of nucleoside antimetabolites.Oral bisphosphonate use and breast cancer incidence in postmenopausal women.The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives.Circulating tumor cell count during zoledronic acid treatment in men with metastatic prostate cancer: a pilot study Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay.In vivo effects of zoledronic acid on oral mucosal epithelial cells Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.The use of bisphosphonates in patients with breast cancer.Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells Proapoptotic and antimetastatic properties of supercritical CO2 extract of Nigella sativa Linn. against breast cancer cells.The potential role of bisphosphonates in prostate cancer.Zoledronic acid (Zometa) use in bone disease.Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours.Tumour macrophages as potential targets of bisphosphonates.In vitro synergistic cytoreductive effects of zoledronic acid and radiation on breast cancer cells.Modelling circulating tumour cells for personalised survival prediction in metastatic breast cancer Advances in the use of bisphosphonates in the prostate cancer setting.The pathophysiology of cancer-induced bone pain: current understanding.Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.

P2860

Q24594269-86387CAD-D57A-46FF-B95D-60A1295C6906 Q24802079-664F6B37-FEAA-451B-AF12-A7003252A705 Q24802119-2249AEF3-AB6F-4967-B6BE-9EC77B2498FF Q24802817-A85CC32C-95F1-44FD-B0A5-A772BB6A3756 Q25255562-8990C8FC-03A0-4729-8548-98840E219D46 Q26795493-90064740-9D02-4424-9417-CAEB0CF15933 Q27028138-CD0B90CF-8DE2-4604-89A3-D9D05F91839B Q27302083-633B45FB-D817-4962-8CDA-CD9D09C0392B Q28361973-D046A3A3-6B4D-47D5-B3C5-619F6FD663FF Q30437441-049F50AD-AE32-43BD-A4A8-0DD1EE5D07DE Q33269187-91D37CB8-D51D-48B8-A08A-244954E806E3 Q33314670-E2E42798-7CCB-46CD-91BC-9979F804D309 Q33415020-AF6034EB-F74C-475C-91F2-1A81D97C6F78 Q33466845-0D969760-2B34-4771-9BBC-A38D01C9FF29 Q33500187-3BDA1DB2-B4A6-42CA-827F-986A0897AFBD Q33587199-DDC3352B-A3AA-4CB3-9FA1-E3033930360C Q33708123-C86FDB89-9960-4D78-93C6-09C1F3A65715 Q33850938-9A08367F-4029-4DA1-8084-1A981808BAB3 Q33880696-0BB35A34-B1A2-4BB9-92F0-19C5C4178D66 Q33926132-CB80A104-AB38-47F1-8836-D20A598468ED Q33941303-14E79648-D49A-41EA-8EBE-A4FA0C27CE32 Q34049239-3B06C9BA-BCDE-49AB-AEEE-E6268B590601 Q34145863-B753493E-2095-417F-930A-9DC82938617E Q34294905-413773F6-B15B-4B72-95C0-BAE8CF0DC13D Q34348233-F6478D4F-5A9D-4309-916C-D216D2A40ED8 Q34441640-A0683B19-E63E-4874-8231-4603157587F5 Q34480630-8C4F7149-29DC-481C-B4E0-A637E2631E5A Q34583705-5D596E86-73F6-4EEA-A733-FB6EE31ACA36 Q35039488-859364B7-F20D-47AB-B2CF-BF71BB56B71D Q35043887-484465D4-960F-4D79-BD3A-3DC0ED0520E5 Q35064914-9DDACA06-9F3A-4B14-B9D0-61B0F11A335F Q35081743-EBF7160B-3176-440D-98BD-1F0DF8361FC7 Q35117725-D27DD9F9-ECB6-4809-89F6-FA7E59308936 Q35208161-88131E65-40B0-4B5C-9CAA-72F3D469F13A Q35547309-0619F3E7-CFBF-49B7-AFD6-4AF1A72ECB93 Q35605757-F26BE32F-0F9E-4ECB-AEBB-2837EEEF5615 Q35610546-9AD9BAD9-FBD0-48C8-8478-2277BC661FD9 Q35679766-387AFAE0-223E-4FFC-80A7-07CC6E2D243C Q35805721-F64DCDFE-6A4F-46FA-BA43-F0661684C3B5 Q35832193-7B2621BF-C226-4D3E-80FA-D12506A8E7D8

P2860

Bisphosphonates induce apoptosis in human breast cancer cell lines

http://www.wikidata.org/entity/Q28344185

description

2000 nî lūn-bûn

@nan

2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Bisphosphonates induce apoptosis in human breast cancer cell lines

@ast

Bisphosphonates induce apoptosis in human breast cancer cell lines

@en

Bisphosphonates induce apoptosis in human breast cancer cell lines

@nl

type

label

Bisphosphonates induce apoptosis in human breast cancer cell lines

@ast

Bisphosphonates induce apoptosis in human breast cancer cell lines

@en

Bisphosphonates induce apoptosis in human breast cancer cell lines

@nl

prefLabel

Bisphosphonates induce apoptosis in human breast cancer cell lines

@ast

Bisphosphonates induce apoptosis in human breast cancer cell lines

@en

Bisphosphonates induce apoptosis in human breast cancer cell lines

@nl

P1433

Q28344185-67E9D141-2DC4-4861-AD72-28F88F23CC8D

P1476

Q28344185-A1EA0FBE-966E-43A2-9201-E24C74426E75

P2093

Q28344185-62BE1615-31F5-42B4-963F-0A4C4AA2E10D

Q28344185-7EB2A1A8-9178-4064-9028-6C44CA8F4123

Q28344185-A8696C0F-8EDB-4BA1-B3FD-AF32C5903285

Q28344185-BB4BC710-E393-4DBC-87F1-50544D4B00DF

Q28344185-C2044124-0447-48AA-AB6F-15A1E8B6A07E

P2860

Q28344185-0D12BC9F-8F0E-4751-B802-DDFB1D5A439C

Q28344185-182E879F-6394-4D74-8DAD-6BE5F97344C1

Q28344185-1B854CD9-A241-4AE8-82FE-6F3DBD502FFE

Q28344185-2268363E-4DFB-4E0D-AEA8-5F1BB6C0F788

Q28344185-25CD9FE1-5817-49FB-B995-C75971EDBE7C

Q28344185-2EF6EF09-D0C2-462B-9EF1-AAF068DD4E5E

Q28344185-34CE25E5-6947-48E8-95C4-3363F705CDF3

Q28344185-354A3701-1405-49F7-8B92-E9533A17CBE2

Q28344185-3D7BF0F6-C108-4D2E-B835-5AB8160DC3D0

Q28344185-41578F5E-A430-4FBC-AABB-8F5ECFEB760B

P2888

Q28344185-D355B918-199A-4B21-B2A0-93735E34E9A7

P304

Q28344185-B200B9BB-2321-44A5-A978-441EBE857FF9

P31

Q28344185-E6865F7C-EC99-4E6F-978C-722237939CB0

P3181

Q28344185-5B267F6C-EFCF-4F96-890D-96896CA198FA

P356

Q28344185-EBBF1F7D-71E5-4513-A978-C9FD4FE44A40

P407

Q28344185-A648EB90-9DCB-4BFC-A994-00FE703198FC

P433

Q28344185-4C19699D-4D0D-436E-ACB3-EE4998934BE8

P478

Q28344185-3246B00D-6DAD-4461-BC70-0AAF063FBA28

P577

Q28344185-5350AACE-AB58-4C85-9D1B-6C64D7BFB211

P5875

Q28344185-3FF18FCD-CB43-4121-ABAC-84ADF88D2F49

P6179

Q28344185-F8C8947D-22C9-49C5-92C3-EB65105CCE02

P698

Q28344185-9B9F899C-7858-40BC-8148-0E2FA8CE1739

P932

Q28344185-2853FF88-A463-4756-9B51-8F080135D737

P3181

P356

P1433

British Journal of Cancer

P1476

Bisphosphonates induce apoptosis in human breast cancer cell lines

@en

P2093

G Pirianov

http://www.w3.org/2001/XMLSchema#string

J L Mansi

http://www.w3.org/2001/XMLSchema#string

K W Colston

http://www.w3.org/2001/XMLSchema#string

S G Senaratne

http://www.w3.org/2001/XMLSchema#string

T R Arnett

http://www.w3.org/2001/XMLSchema#string

P2860

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation

Regulation of cell death protease caspase-9 by phosphorylation

Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase

Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE

Mitochondrial cytochrome c release in apoptosis occurs upstream of DEVD-specific caspase activation and independently of mitochondrial transmembrane depolarization.

Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.

P2888

P304

1459-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

119198

http://www.w3.org/2001/XMLSchema#string

P356

10.1054/BJOC.1999.1131

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

82

http://www.w3.org/2001/XMLSchema#string

P577

2000-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12535296

http://www.w3.org/2001/XMLSchema#string

P6179

1017044437

http://www.w3.org/2001/XMLSchema#string

P698

10780527

http://www.w3.org/2001/XMLSchema#string

P932

2363380

http://www.w3.org/2001/XMLSchema#string